POMALYST with dexamethasone was proven to help patients live longer in a clinical trial
The phase 3 clinical trial was designed to determine if POMALYST with low-dose dexamethasone could be an effective treatment for relapsed multiple myeloma.
A clinical trial studied 455 patients whose MM had stopped responding to at least 2 prior medicines, including REVLIMID® (lenalidomide) and a proteasome inhibitor. A total of 302 patients received POMALYST with low-dose dexamethasone and 153 patients received high-dose dexamethasone alone.
Survival (OS) Results
OS WAS 1.5
What median Overall Survival means
Think of median as the middle value of a set of data points. Overall Survival measures the amount of time patients were alive following the start of the trial.
Median OS for patients taking POMALYST with low-dose dexamethasone was 12.4 months. This is roughly 1.5 times longer than the 8 months that patients lived when they were given high-dose dexamethasone alone.
Survival (PFS) Results
PFS WAS 2 TIMES LONGER
What Progression-Free Survival means
Progression-Free Survival (PFS) measures how long a patient lives without the disease getting worse.
Median PFS for patients taking POMALYST with low-dose dexamethasone was 3.6 months. This was 2 times longer than the 1.8 months that patients lived without their disease getting worse when they were given high-dose dexamethasone alone.
POMALYST may not work for everyone. Ask your doctor if POMALYST with dexamethasone is right for you. Individual results may vary.